Apogee reports positive results from atopic dermatitis drug trial

May 27, 2026 6:30 AM

Apogee Therapeutics Inc. (NASDAQ: APGE) reported positive 16-week results from its Phase 2 APEX trial of zumilokibart for moderate-to-severe atopic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found